nach oben

Journal of Infection and Chemotherapy

Erschienen in:

01.12.2013 | Case Report

Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review

verfasst von: Shojiro Inano, Masahiro Kimura, Jun Iida, Nobuyoshi Arima

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Fusarium spp. cause a broad spectrum of infection and are relatively resistant to most antifungal agents, leading to unfavorable prognosis, especially in immunocompromised patients. Several reports have shown synergism among amphotericin B, voriconazole (VRC), terbinafine (TRB), and other antifungal agents in vitro, but the most efficacious combination remains to be elucidated. We report the first case of disseminated Fusarium solani infection successfully treated by combination therapy of VRC and TRB accompanied by surgical resection of endocardial lesions. We also review 15 case reports of combination antifungal therapy for fusariosis and 6 case reports of Fusarium endocarditis.

Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, Mellado E, Rodríguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother. 2008;61:805–9.

Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(suppl 3):56.PubMedCrossRef

Speeleveld E, Gordts B, Van Landuyt HW, De Vroey C, Raes-Wuytack C. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses. 1996;39:37–40.PubMedCrossRef

Azor M, Gené J, Cano J, Sutton DA, Fothergill AW, Rinaldi MG, et al. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother. 2008;52:2228–31.PubMedCrossRef

Furustrand TU, Meis JF, Trampuz A. Isothermal microcalorimetry for antifungal susceptibility testing of Mucorales, Fusarium spp., and Scedosporium spp. Diagn Microbiol Infect Dis. 2012;73:330–7.CrossRef

Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, Kanioura L, Grammatikou M, Vrioni G, Mitroussia-Ziouva A, et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. Antimicrob Chemother. 2012;67:1937–40.CrossRef

Campo M, Lewis RE, Korntoviannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect. 2010;60:331–7.PubMedCrossRef

Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer (Phila). 2003;98:315–9.CrossRef

Córdoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31:171–4.PubMedCrossRef

10.

Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis. 2004;48:69–71.PubMedCrossRef

11.

Li L, Wang Z, Li R, Luo S, Sun X. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am J Ophthalmol. 2008;146:724–8.PubMedCrossRef

12.

Spader TB, Venturini TP, Cavalheiro AS, Mahl CD, Mario DN, Lara VM, et al. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Mycoses. 2011;54:131–6.PubMedCrossRef

13.

Shalit I, Shadkchan Y, Mircus G, Osherov N. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med Mycol. 2009;47:457–62.PubMedCrossRef

14.

Lau A, Sorrell TC, Chen S, Stanley K, Iredell J, Halliday C. Multiplex tandem PCR: a novel platform for rapid detection and identification of fungal pathogens from blood culture specimens. J Clin Microbiol. 2008;46(9):3021–7.PubMedCrossRef

15.

Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695–704.PubMedCrossRef

16.

Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect. 1994;28(suppl 1):7.PubMedCrossRef

17.

Gamis AS, Gudnason T, Giebink GS, Ramsay NK. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis. 1991;13:1077–88.PubMedCrossRef

18.

Spader TB, Venturini TP, Cavalheiro AS, Mahl CD, Mario DN, Lara VM, et al. Invasive Fusarium solani infections in patients with acute leukemia. Rev Infect Dis. 1988;10:653.CrossRef

19.

Tortorano AM, Prigitano A, Dho G, Esposto MC, Gianni C, Grancini A, et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother. 2008;52:2683.PubMedCrossRef

20.

Speeleveld E, Gordts B, Van Landuyt HW, De Vroey C, Raes-Wuytack C. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses. 1996;39:37.PubMedCrossRef

21.

Fanci R, Pini G, Bartolesi AM, Pecile P. Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review. Rev Iberoam Micol. 2012;. doi:10.1016/j.riam.2012.05.003.PubMed

22.

Liu JY, Chen WT, Ko BS, Yao M, Hsueh PR, Hsiao CH, et al. Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: a case report and literature review. Med Mycol. 2011;49:872–8.PubMed

23.

Vagace JM, Sanz-Rodriguez C, Casado MS, Alonso N, Garcia-Dominguez M, de la Llana FG, Zarallo L, Fajardo M, Bajo R. Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report. BMC Infect Dis. 2007;10:40.CrossRef

24.

Stanzani M, Vianelli N, Bandini G, Paolini S, Arpinati M, Bonifazi F, et al. Successful treatment of disseminated fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. J Infect. 2006;53:e243–6.PubMedCrossRef

25.

Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, Espinel-Ingroff A, Catteau B, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol. 2003;41:4898–900.PubMedCrossRef

26.

Rothe A, Seibold M, Hoppe T, Seifert H, Engert A, Caspar C, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2003;83:394–7.PubMedCrossRef

27.

Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2004;23:1059–61.PubMedCrossRef

28.

Neuburger S, Massenkeil G, Seibold M, Lutz C, Tamm I, le Coutre P, et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis. 2008;10:290–3.PubMedCrossRef

29.

Barrios NJ, Kirkpatrick DV, Murciano A, Stine K, Van Dyke RB, Humbert JR. Successful treatment of disseminated Fusarium infection in an immunocompromised child. Am J Pediatr Hematol Oncol. 1990;12:319–24.PubMedCrossRef

30.

Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses. 2007;50:227–31.PubMedCrossRef

31.

Rodriguez CA, Luján-Zilbermann J, Woodard P, Andreansky M, Adderson EE. Successful treatment of disseminated fusariosis. Bone Marrow Transplant. 2003;31:411–2.PubMedCrossRef

32.

Cuellar-Rodriguez J, Bravo LT, Oethinger M, Fraser T, Mossad SB. Disseminated fusariosis in a recipient of a bone-marrow transplant. Lancet Infect Dis. 2009;9:520.PubMedCrossRef

33.

Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusarium infection originating from paronychia in a neutropenic patient: a case report and review of the literature. Cutis. 2010;85:191–4.PubMed

34.

Makowsky MJ, Warkentin DI, Savoie M. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother. 2005;39:1365–6.PubMedCrossRef

35.

Nunes Mdo C, Barbosa FB, Gomes GH, Bráulio R, Nicoliello MF, Ferrari TC. Fatal right-sided endocarditis caused by Fusarium in an immunocompromised patient: a case report. Mycoses 2011;54:460–462.

36.

Camin AM, Michelet C, Langanay T, de Place C, Chevrier S, Guého E, et al. Endocarditis due to Fusarium dimerum four years after coronary artery bypass grafting. Clin Infect Dis. 1999;28:150.PubMedCrossRef

37.

Guinvarc’h A, Guilbert L, Marmorat-Khuong A, Lavarde V, Chevalier P, Amrein C, et al. Disseminated Fusarium solani infection with endocarditis in a lung transplant recipient. Mycoses. 1998;41:59–61.PubMedCrossRef

38.

Hsu CM, Lee PI, Chen JM, Huang LM, Wu MH, Chiu IS, et al. Fatal Fusarium endocarditis complicated by hemolytic anemia and thrombocytopenia in an infant. Pediatr Infect Dis J. 1994;13:1146–8.PubMedCrossRef

39.

Jorens PG, Van Den Heuvel PA, Van Cauwelaert PA, Parizel GA, Mertens AN. Fusarium endocarditis involving aortic valve following coronary artery surgery. Eur Heart J. 1990;11:476–8.PubMed

40.

Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446–50.PubMedCrossRef

Titel: Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review
verfasst von: Shojiro Inano
Masahiro Kimura
Jun Iida
Nobuyoshi Arima
Publikationsdatum: 01.12.2013
Verlag: Springer Japan
Erschienen in: Journal of Infection and Chemotherapy / Ausgabe 6/2013
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI: https://doi.org/10.1007/s10156-013-0594-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report

Transmission of macrolide-resistant Mycoplasma pneumoniae within a family

Nasopharyngeal tuberculosis

High resolution melting curve assay for rapid detection of drug-resistant Mycobacterium tuberculosis

A case of sepsis caused by Streptococcus canis in a dog owner: a first case report of sepsis without dog bite in Japan

Neonatal hemophagocytic lymphohistiocytosis associated with a vertical transmission of coxsackievirus B1

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin